Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.
Price history
Loading BLRX daily closes…
Loading price history…
Pipeline assets
Motixafortide
Approved · ActiveModality: peptide
Aliases APHEXDA
Target CXCR4
Partnerships Biokine Therapeutics: in-license; Ayrmid License Agreement (November 2024): global rights ex-Asia, all indications other than solid tumors; Gloria License Agreement (October 2023): substantially all of Asia, all indications (planned motixafortide PDAC study in China not advancing on schedule)
Indications
Stem-cell mobilization for autologous transplantation in multiple myeloma(Approved)
Solid tumors(Stage not disclosed)
Status note FDA approved September 8, 2023 (with filgrastim). US commercialization shut down after November 2024 Ayrmid out-license; operations refocused on Israel development. AML indication discontinued; company still sees CXCR4 as viable in other AML lines.
GLIX1
Stage not disclosed · ActiveModality: small molecule (oral)
Target DNA damage response
Partnerships Hemispherian AS: September 2025 collaboration for development, clinical evaluation and commercialization; BioLineRx required to invest $5M in Tetragon Biosciences (GLIX1 vehicle) within 36 months or face equity reduction/repurchase
Indications
Glioblastoma (GBM)(Stage not disclosed)
Other solid tumors(Stage not disclosed)
Status note First-in-class oral small molecule targeting DNA damage response; no clinical trial disclosed in this filing.
Status note In-licensed candidate; no development status disclosed in this filing.
Per-asset detail extracted from the 20-F filed 2026-03-23. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.